Identification

Name
Mefloquine
Accession Number
DB00358  (APRD00300)
Type
Small Molecule
Groups
Approved, Investigational
Description

A phospholipid-interacting antimalarial drug (antimalarials). It is very effective against plasmodium falciparum with very few side effects. [PubChem]

Structure
Thumb
Synonyms
  • [(R*,S*)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol
  • alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
  • Mefloquin
  • Mefloquina
  • Méfloquine
  • Mefloquine
  • Mefloquinum
Product Ingredients
IngredientUNIICASInChI Key
Mefloquine Hydrochloride326VC85GV651742-86-0WESWYMRNZNDGBX-YLCXCWDSSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Lariam Tab 250mgTablet250 mgOralHoffmann La Roche1993-12-312013-05-02Canada
MefloquineTablet250 mgOralAa Pharma Inc2002-07-23Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mefloquine HydrochlorideTablet250 mg/1OralSandoz2002-02-202016-03-31Us
Mefloquine HydrochlorideTablet250 mg/1OralTeva2004-01-06Not applicableUs00555 0171 78 nlmimage10 8e35c70e
Mefloquine HydrochlorideTablet250 mg/1OralA S Medication Solutions2004-01-062017-06-20Us
Mefloquine HydrochlorideTablet250 mg/1OralRebel Distributors2010-04-21Not applicableUs
Mefloquine HydrochlorideTablet250 mg/1OralPhysicians Total Care, Inc.2005-09-26Not applicableUs
Mefloquine HydrochlorideTablet250 mg/1OralWest Ward Pharmaceutical2010-04-21Not applicableUs
Mefloquine HydrochlorideTablet250 mg/1OralPreferreed Pharmaceuticals Inc.2016-11-21Not applicableUs
Mefloquine HydrochlorideTablet250 mg/1OralH.J. Harkins Company2010-04-21Not applicableUs
Mefloquine HydrochlorideTablet250 mg/1OralRebel Distributors2003-12-29Not applicableUs
Mefloquine HydrochlorideTablet250 mg/1OralWest Ward Pharmaceutical2004-10-01Not applicableUs
International/Other Brands
Eloquine (Unifarm) / Facital (Zydus Cadila) / Falcital (Cadila HC) / Lariam (Hoffmann–La Roche) / Larimef (Ipca) / Mefax (Alkem) / Mefliam (Cipla Medpro) / Meflon (ACI) / Mefloquina (AC Farma) / Mefque (Zydus Cadila) / Mephaquin (Hisamitsu Seiyaku) / Mephaquin Lactab (Mepha) / Mequin (Atlantic) / Mqf (Sun) / Suton (Newai Chem) / Tropicur (Investi)
Categories
UNII
TML814419R
CAS number
53230-10-7
Weight
Average: 378.3122
Monoisotopic: 378.116682374
Chemical Formula
C17H16F6N2O
InChI Key
XEEQGYMUWCZPDN-UHFFFAOYSA-N
InChI
InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2
IUPAC Name
[2,8-bis(trifluoromethyl)quinolin-4-yl](piperidin-2-yl)methanol
SMILES
OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F

Pharmacology

Indication

For the treatment of mild to moderate acute malaria caused by Mefloquineuine-susceptible strains of Plasmodium falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. Also for the prophylaxis of Plasmodium falciparum and Plasmodium vivax malaria infections, including prophylaxis of chloroquine-resistant strains of Plasmodium falciparum.

Structured Indications
Pharmacodynamics

Mefloquine is an antimalarial agent which acts as a blood schizonticide. Mefloquine is active against the erythrocytic stages of Plasmodium species. However, the drug has no effect against the exoerythrocytic (hepatic) stages of the parasite. Mefloquine is effective against malaria parasites resistant to chloroquine. Mefloquine is a chiral molecule. According to some research, the (+) enantiomer is more effective in treating malaria, and the (-) enantiomer specifically binds to adenosine receptors in the central nervous system, which may explain some of its psychotropic effects.

Mechanism of action

Mefloquine has been found to produce swelling of the Plasmodium falciparum food vacuoles. It may act by forming toxic complexes with free heme that damage membranes and interact with other plasmodial components.

TargetActionsOrganism
AFe(II)-protoporphyrin IX
antagonist
Plasmodium falciparum
AHemoglobin subunit alpha
antagonist
Human
UAdenosine receptor A2a
antagonist
Human
Absorption

Well absorbed from the gastrointestinal tract. The presence of food significantly enhances the rate and extent of absorption.

Volume of distribution
  • 20 L/kg [healthy adults]
Protein binding

98%

Metabolism

Hepatic. Two metabolites have been identified in humans. The main metabolite, 2,8-bis-trifluoromethyl-4-quinoline carboxylic acid, is inactive against Plasmodium falciparum. The second metabolite, an alcohol, is present in minute quantities.

Route of elimination

There is evidence that mefloquine is excreted mainly in the bile and feces. Urinary excretion of unchanged mefloquine and its main metabolite under steady-state condition accounted for about 9% and 4% of the dose, respectively.

Half life

2 to 4 weeks

Clearance
  • 30 mL/min
Toxicity

Oral, rat: LD50 = 880 mg/kg. Symptoms of overdose include nausea, vomiting, and weight loss.

Affected organisms
  • Plasmodium
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Mefloquine.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Mefloquine.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Mefloquine.Experimental, Illicit
7-NitroindazoleThe therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Mefloquine.Experimental
AcebutololMefloquine may increase the bradycardic activities of Acebutolol.Approved, Investigational
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Mefloquine.Approved, Vet Approved
AceprometazineThe serum concentration of Aceprometazine can be increased when it is combined with Mefloquine.Approved
AcetazolamideThe therapeutic efficacy of Acetazolamide can be decreased when used in combination with Mefloquine.Approved, Vet Approved
Acetyl sulfisoxazoleThe metabolism of Mefloquine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Acetylcholine.Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Mefloquine.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Mefloquine.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Mefloquine.Approved
AlcuroniumThe therapeutic efficacy of Alcuronium can be decreased when used in combination with Mefloquine.Experimental
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Mefloquine.Experimental, Investigational
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Mefloquine.Approved, Vet Approved
AlprenololMefloquine may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Mefloquine.Approved
AmiodaroneThe metabolism of Mefloquine can be decreased when combined with Amiodarone.Approved, Investigational
AmodiaquineThe risk or severity of adverse effects can be increased when Amodiaquine is combined with Mefloquine.Approved, Investigational
AnagrelideMefloquine may increase the QTc-prolonging activities of Anagrelide.Approved
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Mefloquine.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Mefloquine.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Mefloquine.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Mefloquine.Approved
Anthranilic acidThe therapeutic efficacy of Anthranilic acid can be decreased when used in combination with Mefloquine.Experimental
ApalutamideThe serum concentration of Mefloquine can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Mefloquine can be increased when it is combined with Aprepitant.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Arecoline.Experimental
ArotinololMefloquine may increase the bradycardic activities of Arotinolol.Investigational
Arsenic trioxideMefloquine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Artemether.Approved
AsenapineMefloquine may increase the QTc-prolonging activities of Asenapine.Approved
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Mefloquine.Approved, Investigational, Withdrawn
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Mefloquine.Investigational
AtazanavirThe metabolism of Mefloquine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololMefloquine may increase the bradycardic activities of Atenolol.Approved
AtomoxetineThe metabolism of Mefloquine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Mefloquine is combined with Atorvastatin.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be decreased when used in combination with Mefloquine.Approved, Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Mefloquine.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Mefloquine.Approved, Vet Approved
AzithromycinMefloquine may increase the QTc-prolonging activities of Azithromycin.Approved
BarbexacloneThe therapeutic efficacy of Barbexaclone can be decreased when used in combination with Mefloquine.Experimental
BeclamideThe therapeutic efficacy of Beclamide can be decreased when used in combination with Mefloquine.Experimental
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Mefloquine.Approved, Investigational
BedaquilineMefloquine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololMefloquine may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Mefloquine.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Mefloquine.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Mefloquine.Approved, Vet Approved
BetaxololMefloquine may increase the bradycardic activities of Betaxolol.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Mefloquine is combined with Bethanechol.Approved
BevantololMefloquine may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Mefloquine.Approved, Investigational
BisoprololMefloquine may increase the bradycardic activities of Bisoprolol.Approved
BL-1020The serum concentration of BL-1020 can be increased when it is combined with Mefloquine.Investigational
BoceprevirThe metabolism of Mefloquine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololMefloquine may increase the bradycardic activities of Bopindolol.Approved
BornaprineThe therapeutic efficacy of Bornaprine can be decreased when used in combination with Mefloquine.Experimental
BortezomibThe metabolism of Mefloquine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Mefloquine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Mefloquine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mefloquine.Approved, Investigational
BrivaracetamThe therapeutic efficacy of Brivaracetam can be decreased when used in combination with Mefloquine.Approved, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mefloquine.Approved, Investigational
BucindololMefloquine may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Mefloquine.Approved
BufuralolMefloquine may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupranololMefloquine may increase the bradycardic activities of Bupranolol.Approved
ButylscopolamineThe therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Mefloquine.Approved, Investigational, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Mefloquine.Approved
CarbacholThe risk or severity of adverse effects can be increased when Mefloquine is combined with Carbachol.Approved
CarbamazepineThe therapeutic efficacy of Carbamazepine can be decreased when used in combination with Mefloquine.Approved, Investigational
CarisbamateThe therapeutic efficacy of Carisbamate can be decreased when used in combination with Mefloquine.Investigational
CarteololMefloquine may increase the bradycardic activities of Carteolol.Approved
CarvedilolMefloquine may increase the bradycardic activities of Carvedilol.Approved, Investigational
CeliprololMefloquine may increase the bradycardic activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Mefloquine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Mefloquine.Approved, Withdrawn
CevimelineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Cevimeline.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mefloquine.Approved, Investigational, Vet Approved
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Mefloquine.Withdrawn
ChlorproethazineThe serum concentration of Chlorproethazine can be increased when it is combined with Mefloquine.Experimental
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Mefloquine.Approved, Investigational, Vet Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Mefloquine.Approved, Investigational
CiprofloxacinMefloquine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideMefloquine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramMefloquine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe metabolism of Mefloquine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Mefloquine can be decreased when combined with Clemastine.Approved, Investigational
ClobazamThe therapeutic efficacy of Clobazam can be decreased when used in combination with Mefloquine.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Mefloquine.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Mefloquine.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Mefloquine.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Mefloquine.Approved
clomethiazoleThe therapeutic efficacy of clomethiazole can be decreased when used in combination with Mefloquine.Investigational
ClonazepamThe therapeutic efficacy of Clonazepam can be decreased when used in combination with Mefloquine.Approved, Illicit
CloranololMefloquine may increase the bradycardic activities of Cloranolol.Experimental
ClorazepateThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Mefloquine.Approved, Illicit
ClotrimazoleThe metabolism of Mefloquine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineMefloquine may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe metabolism of Mefloquine can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Mefloquine.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Mefloquine.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Mefloquine.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Mefloquine.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Mefloquine.Approved, Investigational
CrizotinibThe metabolism of Mefloquine can be decreased when combined with Crizotinib.Approved
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Mefloquine.Approved
CyclosporineThe metabolism of Mefloquine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mefloquine.Approved
DabrafenibThe serum concentration of Mefloquine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DapsoneThe risk or severity of adverse effects can be increased when Mefloquine is combined with Dapsone.Approved, Investigational
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Mefloquine.Approved, Investigational
DarunavirThe metabolism of Mefloquine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Mefloquine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Mefloquine can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Mefloquine.Approved, Investigational
DelavirdineThe metabolism of Mefloquine can be decreased when combined with Delavirdine.Approved
DelorazepamThe therapeutic efficacy of Delorazepam can be decreased when used in combination with Mefloquine.Approved, Illicit, Investigational
DeramciclaneThe therapeutic efficacy of Deramciclane can be decreased when used in combination with Mefloquine.Investigational
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Mefloquine.Approved, Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Mefloquine.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Mefloquine.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Mefloquine.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Mefloquine.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Mefloquine.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Mefloquine.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Mefloquine.Withdrawn
DiazepamThe therapeutic efficacy of Diazepam can be decreased when used in combination with Mefloquine.Approved, Illicit, Investigational, Vet Approved
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Mefloquine.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Mefloquine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Mefloquine.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Mefloquine.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Mefloquine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Mefloquine.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Mefloquine.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Mefloquine.Approved, Investigational
DiltiazemThe metabolism of Mefloquine can be decreased when combined with Diltiazem.Approved, Investigational
DiphenhydramineThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Mefloquine.Approved, Investigational
DipyridamoleThe therapeutic efficacy of Mefloquine can be decreased when used in combination with Dipyridamole.Approved
DisopyramideMefloquine may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideMefloquine may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronMefloquine may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
DomperidoneMefloquine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe therapeutic efficacy of Doramectin can be decreased when used in combination with Mefloquine.Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Mefloquine.Approved, Investigational
DoxycyclineThe metabolism of Mefloquine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneMefloquine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolMefloquine may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Mefloquine.Approved
EliglustatMefloquine may increase the QTc-prolonging activities of Eliglustat.Approved
EmeproniumThe therapeutic efficacy of Emepronium can be decreased when used in combination with Mefloquine.Experimental
EnzalutamideThe serum concentration of Mefloquine can be decreased when it is combined with Enzalutamide.Approved
EpanololMefloquine may increase the bradycardic activities of Epanolol.Experimental
EperisoneThe therapeutic efficacy of Eperisone can be decreased when used in combination with Mefloquine.Approved, Investigational
EpibatidineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Epibatidine.Experimental
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Mefloquine.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Mefloquine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Mefloquine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Mefloquine.Approved
ErythromycinThe metabolism of Mefloquine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramMefloquine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Mefloquine.Approved
EsmololMefloquine may increase the bradycardic activities of Esmolol.Approved
EstazolamThe therapeutic efficacy of Estazolam can be decreased when used in combination with Mefloquine.Approved, Illicit
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Mefloquine.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Mefloquine.Approved
EtanautineThe therapeutic efficacy of Etanautine can be decreased when used in combination with Mefloquine.Experimental
EthadioneThe therapeutic efficacy of Ethadione can be decreased when used in combination with Mefloquine.Experimental
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Mefloquine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mefloquine.Approved
EthotoinThe therapeutic efficacy of Ethotoin can be decreased when used in combination with Mefloquine.Approved
EtiracetamThe therapeutic efficacy of Etiracetam can be decreased when used in combination with Mefloquine.Investigational
EtybenzatropineThe therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Mefloquine.Experimental
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Mefloquine.Approved
EzogabineThe therapeutic efficacy of Ezogabine can be decreased when used in combination with Mefloquine.Approved, Investigational
FelbamateThe therapeutic efficacy of Felbamate can be decreased when used in combination with Mefloquine.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mefloquine.Approved
FlavoxateThe therapeutic efficacy of Flavoxate can be decreased when used in combination with Mefloquine.Approved
FlecainideMefloquine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Mefloquine.Investigational
FluconazoleThe metabolism of Mefloquine can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe therapeutic efficacy of Fludiazepam can be decreased when used in combination with Mefloquine.Approved, Illicit
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Mefloquine.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Mefloquine.Approved, Vet Approved
FlunarizineThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Mefloquine.Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Mefloquine.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Mefloquine.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Mefloquine.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Mefloquine.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Mefloquine.Approved, Investigational
FluoxetineMefloquine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolMefloquine may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Mefloquine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Mefloquine.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Mefloquine.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Mefloquine.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Mefloquine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Mefloquine.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Mefloquine.Approved
FluvoxamineThe metabolism of Mefloquine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Mefloquine.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Mefloquine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Mefloquine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Mefloquine.Approved, Investigational
Fusidic AcidThe serum concentration of Mefloquine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Mefloquine.Approved, Investigational
GaboxadolThe therapeutic efficacy of Gaboxadol can be decreased when used in combination with Mefloquine.Investigational
Gadobenic acidMefloquine may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GallamineThe therapeutic efficacy of Gallamine can be decreased when used in combination with Mefloquine.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Mefloquine.Approved
GemifloxacinMefloquine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Mefloquine.Approved, Investigational, Vet Approved
GoserelinMefloquine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronMefloquine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GTS-21The risk or severity of adverse effects can be increased when Mefloquine is combined with GTS-21.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Mefloquine.Approved, Investigational, Withdrawn
HalofantrineMefloquine may increase the QTc-prolonging activities of Halofantrine.Approved
HaloperidolMefloquine may increase the QTc-prolonging activities of Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Mefloquine.Investigational
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Mefloquine.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Mefloquine.Approved, Vet Approved
HydroxychloroquineThe risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Mefloquine.Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Mefloquine.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Mefloquine.Approved
IbutilideMefloquine may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe metabolism of Mefloquine can be decreased when combined with Idelalisib.Approved
IfenprodilThe therapeutic efficacy of Ifenprodil can be decreased when used in combination with Mefloquine.Approved, Investigational, Withdrawn
IloperidoneMefloquine may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Mefloquine can be decreased when combined with Imatinib.Approved
IndenololMefloquine may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe metabolism of Mefloquine can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Mefloquine.Approved
IsavuconazoleThe serum concentration of Mefloquine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Mefloquine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Mefloquine can be decreased when combined with Isradipine.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Mefloquine.Investigational
ItraconazoleThe metabolism of Mefloquine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Mefloquine can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Mefloquine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolMefloquine may increase the bradycardic activities of Labetalol.Approved
LacosamideThe therapeutic efficacy of Lacosamide can be decreased when used in combination with Mefloquine.Approved
LamotrigineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Mefloquine.Approved, Investigational
LandiololMefloquine may increase the bradycardic activities of Landiolol.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Mefloquine.Approved
LenvatinibMefloquine may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LeuprolideMefloquine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Mefloquine.Approved, Investigational
LevobunololMefloquine may increase the bradycardic activities of Levobunolol.Approved
LevofloxacinMefloquine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Mefloquine.Approved, Investigational
LobelineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Lobeline.Investigational
LopinavirThe metabolism of Mefloquine can be decreased when combined with Lopinavir.Approved
LorazepamThe therapeutic efficacy of Lorazepam can be decreased when used in combination with Mefloquine.Approved
LorpiprazoleThe serum concentration of Mefloquine can be increased when it is combined with Lorpiprazole.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Mefloquine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Mefloquine.Approved, Investigational
LuliconazoleThe serum concentration of Mefloquine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Mefloquine can be increased when combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Lumefantrine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Mefloquine.Illicit, Investigational, Withdrawn
Magnesium sulfateThe therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Mefloquine.Approved, Investigational, Vet Approved
MazaticolThe therapeutic efficacy of Mazaticol can be decreased when used in combination with Mefloquine.Experimental
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Mefloquine.Investigational
MebeverineThe therapeutic efficacy of Mebeverine can be decreased when used in combination with Mefloquine.Approved, Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Mefloquine.Approved, Investigational
MedazepamThe therapeutic efficacy of Medazepam can be decreased when used in combination with Mefloquine.Experimental
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Mefloquine.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Mefloquine.Vet Approved
MephenytoinThe therapeutic efficacy of Mephenytoin can be decreased when used in combination with Mefloquine.Investigational, Withdrawn
MepindololMefloquine may increase the bradycardic activities of Mepindolol.Experimental
MeprobamateThe therapeutic efficacy of Meprobamate can be decreased when used in combination with Mefloquine.Approved, Illicit
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Mefloquine.Approved, Investigational
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Mefloquine.Experimental
MethacholineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Methacholine.Approved, Investigational
MethadoneMefloquine may increase the QTc-prolonging activities of Methadone.Approved
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Mefloquine.Approved, Investigational
MetharbitalThe therapeutic efficacy of Metharbital can be decreased when used in combination with Mefloquine.Withdrawn
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Mefloquine.Approved, Investigational
MethscopolamineThe therapeutic efficacy of Methscopolamine can be decreased when used in combination with Mefloquine.Approved
MethsuximideThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Mefloquine.Approved
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Mefloquine.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Mefloquine.Approved
MethylphenobarbitalThe therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Mefloquine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Mefloquine.Approved, Vet Approved
Methylscopolamine bromideThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Mefloquine.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Mefloquine.Approved
MetipranololMefloquine may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Mefloquine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Mefloquine.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Mefloquine.Experimental
MifepristoneThe serum concentration of Mefloquine can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Mefloquine can be decreased when it is combined with Mitotane.Approved
MivacuriumMefloquine may decrease the neuromuscular blocking activities of Mivacurium.Approved
MK-212The therapeutic efficacy of MK-212 can be decreased when used in combination with Mefloquine.Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Mefloquine.Approved, Vet Approved
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Mefloquine.Approved, Investigational, Withdrawn
MoxifloxacinMefloquine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NadololMefloquine may increase the bradycardic activities of Nadolol.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Mefloquine.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Mefloquine.Investigational
NebivololMefloquine may increase the bradycardic activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Mefloquine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Mefloquine can be decreased when combined with Nelfinavir.Approved
NeocitrullamonThe therapeutic efficacy of Neocitrullamon can be decreased when used in combination with Mefloquine.Experimental
NetupitantThe serum concentration of Mefloquine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Mefloquine can be increased when combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Mefloquine.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Nicotine.Approved
NilotinibMefloquine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Mefloquine.Approved
NitrazepamThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Mefloquine.Approved
OfloxacinMefloquine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlaparibThe metabolism of Mefloquine can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Mefloquine.Investigational
OndansetronMefloquine may increase the QTc-prolonging activities of Ondansetron.Approved
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Mefloquine.Approved
OsimertinibThe serum concentration of Mefloquine can be increased when it is combined with Osimertinib.Approved
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Mefloquine.Experimental, Investigational
OxcarbazepineThe therapeutic efficacy of Oxcarbazepine can be decreased when used in combination with Mefloquine.Approved
OxitropiumThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Mefloquine.Investigational
OxprenololMefloquine may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Mefloquine.Approved, Investigational
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Mefloquine.Approved
PalbociclibThe serum concentration of Mefloquine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneMefloquine may increase the QTc-prolonging activities of Paliperidone.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Mefloquine.Approved
PanobinostatMefloquine may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParaldehydeThe therapeutic efficacy of Paraldehyde can be decreased when used in combination with Mefloquine.Approved, Investigational
ParamethadioneThe therapeutic efficacy of Paramethadione can be decreased when used in combination with Mefloquine.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Mefloquine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Mefloquine.Approved
PenbutololMefloquine may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentamidineMefloquine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
PentobarbitalThe metabolism of Mefloquine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Mefloquine.Approved
PerampanelThe therapeutic efficacy of Perampanel can be decreased when used in combination with Mefloquine.Approved
PerazineThe serum concentration of Perazine can be increased when it is combined with Mefloquine.Approved, Investigational
PerflutrenMefloquine may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Mefloquine.Approved, Investigational, Vet Approved, Withdrawn
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Mefloquine.Approved
PhenacemideThe therapeutic efficacy of Phenacemide can be decreased when used in combination with Mefloquine.Approved
PheneturideThe therapeutic efficacy of Pheneturide can be decreased when used in combination with Mefloquine.Experimental
PhenglutarimideThe therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Mefloquine.Experimental
PhenibutThe therapeutic efficacy of Phenibut can be decreased when used in combination with Mefloquine.Experimental
PhenobarbitalThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Mefloquine.Approved, Investigational
PhensuximideThe therapeutic efficacy of Phensuximide can be decreased when used in combination with Mefloquine.Approved
PhenytoinThe therapeutic efficacy of Phenytoin can be decreased when used in combination with Mefloquine.Approved, Vet Approved
PilocarpineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Pilocarpine.Approved, Investigational
PimozideMefloquine may increase the QTc-prolonging activities of Pimozide.Approved
PindololMefloquine may increase the bradycardic activities of Pindolol.Approved, Investigational
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Mefloquine.Approved
PipequalineThe therapeutic efficacy of Pipequaline can be decreased when used in combination with Mefloquine.Experimental
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Mefloquine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Mefloquine.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Mefloquine.Approved, Investigational
Platelet Activating FactorMefloquine may increase the bradycardic activities of Platelet Activating Factor.Experimental
PosaconazoleThe metabolism of Mefloquine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololMefloquine may increase the bradycardic activities of Practolol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Mefloquine.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Mefloquine.Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Mefloquine.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Mefloquine.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Mefloquine.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Mefloquine.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Mefloquine.Approved, Illicit, Investigational
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Mefloquine.Approved, Experimental, Investigational
PrimaquineThe risk or severity of adverse effects can be increased when Primaquine is combined with Mefloquine.Approved
PrimidoneThe therapeutic efficacy of Primidone can be decreased when used in combination with Mefloquine.Approved, Vet Approved
ProcainamideMefloquine may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Mefloquine.Approved, Vet Approved
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Mefloquine.Approved
ProgabideThe therapeutic efficacy of Progabide can be decreased when used in combination with Mefloquine.Approved, Investigational
PromazineThe serum concentration of Promazine can be increased when it is combined with Mefloquine.Approved, Vet Approved
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Mefloquine.Approved, Investigational
PropafenoneMefloquine may increase the QTc-prolonging activities of Propafenone.Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Mefloquine.Approved
PropericiazineThe serum concentration of Propericiazine can be increased when it is combined with Mefloquine.Approved, Investigational
PropiopromazineThe serum concentration of Propiopromazine can be increased when it is combined with Mefloquine.Vet Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Mefloquine.Approved, Investigational
PropranololMefloquine may increase the bradycardic activities of Propranolol.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Mefloquine.Approved
QuetiapineMefloquine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Mefloquine.Approved, Investigational
QuinineThe risk or severity of adverse effects can be increased when Quinine is combined with Mefloquine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Mefloquine.Approved, Investigational
RapacuroniumMefloquine may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RemacemideThe therapeutic efficacy of Remacemide can be decreased when used in combination with Mefloquine.Investigational
RifabutinThe metabolism of Mefloquine can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Mefloquine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Mefloquine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Mefloquine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Mefloquine.Approved
RiluzoleThe therapeutic efficacy of Riluzole can be decreased when used in combination with Mefloquine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Mefloquine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Mefloquine.Approved
RucaparibThe metabolism of Mefloquine can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe therapeutic efficacy of Rufinamide can be decreased when used in combination with Mefloquine.Approved
SaquinavirThe metabolism of Mefloquine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Mefloquine can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Mefloquine.Approved, Investigational
SildenafilThe metabolism of Mefloquine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Mefloquine.Approved
SiltuximabThe serum concentration of Mefloquine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Mefloquine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Mefloquine.Approved
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Mefloquine.Approved
SotalolMefloquine may increase the QTc-prolonging activities of Sotalol.Approved
St. John's WortThe serum concentration of Mefloquine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe therapeutic efficacy of Stiripentol can be decreased when used in combination with Mefloquine.Approved
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Mefloquine.Approved
SulfisoxazoleThe metabolism of Mefloquine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulthiameThe therapeutic efficacy of Sulthiame can be decreased when used in combination with Mefloquine.Experimental
TafenoquineThe risk or severity of adverse effects can be increased when Tafenoquine is combined with Mefloquine.Investigational
TalinololMefloquine may increase the bradycardic activities of Talinolol.Investigational
TelaprevirThe metabolism of Mefloquine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinMefloquine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Mefloquine can be decreased when combined with Telithromycin.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Mefloquine.Experimental
TertatololMefloquine may increase the bradycardic activities of Tertatolol.Experimental
TetrabenazineMefloquine may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
ThiazinamThe serum concentration of Thiazinam can be increased when it is combined with Mefloquine.Experimental
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Mefloquine.Withdrawn
ThiopentalThe therapeutic efficacy of Thiopental can be decreased when used in combination with Mefloquine.Approved, Vet Approved
ThioproperazineThe serum concentration of Thioproperazine can be increased when it is combined with Mefloquine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Mefloquine.Approved, Withdrawn
TiagabineThe therapeutic efficacy of Tiagabine can be decreased when used in combination with Mefloquine.Approved, Investigational
TiclopidineThe metabolism of Mefloquine can be decreased when combined with Ticlopidine.Approved
TiletamineThe therapeutic efficacy of Tiletamine can be decreased when used in combination with Mefloquine.Vet Approved
TimololMefloquine may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Mefloquine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Mefloquine.Approved, Withdrawn
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Mefloquine.Approved, Investigational
TocilizumabThe serum concentration of Mefloquine can be decreased when it is combined with Tocilizumab.Approved
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Mefloquine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Mefloquine.Approved
TopiramateThe therapeutic efficacy of Topiramate can be decreased when used in combination with Mefloquine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Mefloquine.Approved, Investigational
ToremifeneMefloquine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramiprosateThe therapeutic efficacy of Tramiprosate can be decreased when used in combination with Mefloquine.Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Mefloquine.Approved, Vet Approved
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Mefloquine.Approved, Investigational
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Mefloquine.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Mefloquine.Approved
TrimethadioneThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Mefloquine.Approved
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Mefloquine.Approved, Investigational
TropatepineThe therapeutic efficacy of Tropatepine can be decreased when used in combination with Mefloquine.Experimental
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Mefloquine.Approved, Investigational
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Mefloquine.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Mefloquine.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Mefloquine.Approved
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Mefloquine.Approved
Valproic AcidThe therapeutic efficacy of Valproic Acid can be decreased when used in combination with Mefloquine.Approved, Investigational
ValpromideThe therapeutic efficacy of Valpromide can be decreased when used in combination with Mefloquine.Experimental
VandetanibMefloquine may increase the QTc-prolonging activities of Vandetanib.Approved
VareniclineThe risk or severity of adverse effects can be increased when Mefloquine is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Mefloquine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Mefloquine.Approved
VenlafaxineThe metabolism of Mefloquine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Mefloquine can be decreased when combined with Verapamil.Approved
VigabatrinThe therapeutic efficacy of Vigabatrin can be decreased when used in combination with Mefloquine.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Mefloquine.Approved, Investigational
VinpocetineThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Mefloquine.Investigational
VoriconazoleThe metabolism of Mefloquine can be decreased when combined with Voriconazole.Approved, Investigational
ZaleplonThe therapeutic efficacy of Zaleplon can be decreased when used in combination with Mefloquine.Approved, Illicit, Investigational
ZiprasidoneMefloquine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZonisamideThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Mefloquine.Approved, Investigational
ZuclopenthixolMefloquine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with a full glass of water.
  • Take with food.

References

Synthesis Reference
US4507482
General References
Not Available
External Links
Human Metabolome Database
HMDB0014502
KEGG Drug
D04895
KEGG Compound
C07633
PubChem Compound
4046
PubChem Substance
46505610
ChemSpider
3906
BindingDB
50022889
ChEBI
63681
ChEMBL
CHEMBL416956
Therapeutic Targets Database
DAP001310
PharmGKB
PA450348
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Mefloquine
ATC Codes
P01BF02 — Artesunate and mefloquineP01BC02 — Mefloquine
AHFS Codes
  • 08:30.08 — Antimalarials
FDA label
Download (394 KB)
MSDS
Download (107 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentBrain Cancer1
1CompletedPreventionMalaria in Pregnant HIV + Patients1
1RecruitingTreatmentAcute Falciparum Malaria1
1, 2TerminatedTreatmentProgressive Multifocal Leukoencephalopathy1
2CompletedTreatmentFalciparum Parasitaemia1
2CompletedTreatmentPlasmodium Infections1
2CompletedTreatmentUrinary Schistosomiasis1
2, 3CompletedDiagnosticPlasmodium Infections1
2, 3CompletedTreatmentMalaria caused by Plasmodium falciparum1
2, 3WithdrawnTreatmentUncomplicated Falciparum Malaria1
3CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Malaria in Pregnancy1
3CompletedPreventionPlasmodium Infections1
3CompletedTreatmentPlasmodium Infections2
3Not Yet RecruitingTreatmentPlasmodium Falciparum1
4CompletedTreatmentFalciparum / Plasmodium Infections1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentPlasmodium Infections3
4RecruitingPreventionParasitic Diseases / Plasmodium Infections1
4Unknown StatusTreatmentMalaria caused by Plasmodium falciparum1
4Unknown StatusTreatmentUncomplicated Falciparum Malaria1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections / Pregnancy1
Not AvailableCompletedSupportive CareHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
Not AvailableCompletedTreatmentMalaria caused by Plasmodium falciparum1
Not AvailableCompletedTreatmentP. Falciparum Malaria1
Not AvailableCompletedTreatmentPlasmodium Falciparum Malaria1
Not AvailableCompletedTreatmentPlasmodium Infections1

Pharmacoeconomics

Manufacturers
  • Hoffmann la roche inc
  • Barr laboratories inc
  • Roxane laboratories inc
  • Sandoz inc
  • United states army walter reed army institute research
  • West ward pharmaceutical corp
Packagers
  • A-S Medication Solutions LLC
  • Barr Pharmaceuticals
  • Dispensing Solutions
  • F Hoffmann La Roche Ltd.
  • F Hoffmann-La Roche Ltd.
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Roxane Labs
  • Sandoz
  • West-Ward Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral250 mg
TabletOral250 mg/1
Prices
Unit descriptionCostUnit
Lariam 25 250 mg tablet Box322.77USD box
Lariam 250 mg tablet12.41USD tablet
Mefloquine hcl 250 mg tablet10.8USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility5000 mg/L (HCl salt)Not Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.038 mg/mLALOGPS
logP3.1ALOGPS
logP4.11ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)13.79ChemAxon
pKa (Strongest Basic)9.46ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area45.15 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity82.58 m3·mol-1ChemAxon
Polarizability31.73 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9959
Blood Brain Barrier+0.9445
Caco-2 permeable-0.5753
P-glycoprotein substrateSubstrate0.6796
P-glycoprotein inhibitor INon-inhibitor0.7395
P-glycoprotein inhibitor IIInhibitor0.5419
Renal organic cation transporterNon-inhibitor0.6446
CYP450 2C9 substrateNon-substrate0.8711
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6524
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8533
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9163
Ames testNon AMES toxic0.809
CarcinogenicityNon-carcinogens0.9437
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9133 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9035
hERG inhibition (predictor II)Inhibitor0.8204
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 4-quinolinemethanols. These are organoheterocyclic compounds containing a quinoline moiety substituted at the 4-position with a methanol.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
4-quinolinemethanols
Direct Parent
4-quinolinemethanols
Alternative Parents
Aralkylamines / Pyridines and derivatives / Piperidines / Benzenoids / Heteroaromatic compounds / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Azacyclic compounds / Organopnictogen compounds
show 4 more
Substituents
4-quinolinemethanol / Aralkylamine / Piperidine / Pyridine / Benzenoid / Heteroaromatic compound / 1,2-aminoalcohol / Secondary alcohol / Secondary aliphatic amine / Secondary amine
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
piperidines, organofluorine compound, quinolines, secondary alcohol (CHEBI:63681)

Targets

1. Fe(II)-protoporphyrin IX
Kind
Small molecule
Organism
Plasmodium falciparum
Pharmacological action
Yes
Actions
Antagonist
References
  1. Fitch CD: Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci. 2004 Mar 5;74(16):1957-72. [PubMed:14967191]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Oxygen transporter activity
Specific Function
Involved in oxygen transport from the lung to the various peripheral tissues.
Gene Name
HBA1
Uniprot ID
P69905
Uniprot Name
Hemoglobin subunit alpha
Molecular Weight
15257.405 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Details
3. Adenosine receptor A2a
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Identical protein binding
Specific Function
Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
Gene Name
ADORA2A
Uniprot ID
P29274
Uniprot Name
Adenosine receptor A2a
Molecular Weight
44706.925 Da
References
  1. Gillespie RJ, Adams DR, Bebbington D, Benwell K, Cliffe IA, Dawson CE, Dourish CT, Fletcher A, Gaur S, Giles PR, Jordan AM, Knight AR, Knutsen LJ, Lawrence A, Lerpiniere J, Misra A, Porter RH, Pratt RM, Shepherd R, Upton R, Ward SE, Weiss SM, Williamson DS: Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2916-9. doi: 10.1016/j.bmcl.2008.03.075. Epub 2008 Mar 30. [PubMed:18406614]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Lim LY, Go ML: The anticholinesterase activity of mefloquine. Clin Exp Pharmacol Physiol. 1985 Sep-Oct;12(5):527-31. [PubMed:3878759]
  2. Zhou C, Xiao C, McArdle JJ, Ye JH: Mefloquine enhances nigral gamma-aminobutyric acid release via inhibition of cholinesterase. J Pharmacol Exp Ther. 2006 Jun;317(3):1155-60. Epub 2006 Feb 24. [PubMed:16501066]
  3. McArdle JJ, Sellin LC, Coakley KM, Potian JG, Quinones-Lopez MC, Rosenfeld CA, Sultatos LG, Hognason K: Mefloquine inhibits cholinesterases at the mouse neuromuscular junction. Neuropharmacology. 2005 Dec;49(8):1132-9. Epub 2005 Aug 2. [PubMed:16081111]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serine hydrolase activity
Specific Function
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name
ACHE
Uniprot ID
P22303
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
  1. Lim LY, Go ML: The anticholinesterase activity of mefloquine. Clin Exp Pharmacol Physiol. 1985 Sep-Oct;12(5):527-31. [PubMed:3878759]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Fujita R, Ishikawa M, Takayanagi M, Takayanagi Y, Sasaki K: Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine. Methods Find Exp Clin Pharmacol. 2000 Jun;22(5):281-4. [PubMed:11031728]

Drug created on June 13, 2005 07:24 / Updated on May 26, 2018 08:45